Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
ROCKVILLE, Md. and SUZHOU, China, Nov. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for...
Trinasolar announces efficiency of 26.58% for n-type TOPCon cells, setting the 28th world record
CHANGZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Trinasolar announced that its industrial larger-area 350.4 cm2 n-type bifacial i-TOPCon solar cells has achieved 26.58% efficiency, setting a new record for large-area industrial TOPCon solar cell....
FWD Group and BRI Life become INSEAD case study
SINGAPORE and HONG KONG, Nov. 21, 2024 /PRNewswire/ -- FWD Group Holdings Limited ("FWD Group" or "FWD") today announced at an on-campus event in Singapore that its strategic partnership with PT Asuransi BRI Life ("BRI Life") will become a case...